Entero Therapeutics, Inc. (NASDAQ:ENTO – Get Free Report) shares shot up 15.2% during mid-day trading on Friday . The stock traded as high as $4.10 and last traded at $3.79. 396,905 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 2,798,922 shares. The stock had previously closed at $3.29.
Entero Therapeutics Trading Up 10.0%
The firm has a market capitalization of $6.62 million, a P/E ratio of -2.47 and a beta of 1.19. The business’s fifty day moving average is $4.12 and its 200 day moving average is $3.37.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in shares of Entero Therapeutics during the 3rd quarter valued at $59,000. GSA Capital Partners LLP acquired a new position in shares of Entero Therapeutics in the 2nd quarter worth $65,000. Persistent Asset Partners Ltd acquired a new position in shares of Entero Therapeutics in the 2nd quarter worth $198,000. Elmind Capital LP acquired a new stake in shares of Entero Therapeutics during the second quarter worth $363,300,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Entero Therapeutics during the second quarter worth $3,642,000. Institutional investors own 12.30% of the company’s stock.
About Entero Therapeutics
Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.
Entero’s pipeline features multiple lead candidates in varying stages of clinical development.
See Also
- Five stocks we like better than Entero Therapeutics
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
